Tauklarify imaging is an FDA-approved brain PET scan that identifies tau tangle pathology in adults with cognitive impairment being evaluated for Alzheimer's disease. Tau tangles are twisted clumps of tau protein inside brain cells that disrupt cell function and memory.
The approval came on Aug. 14, 2026, for Tauklarify (florquinitau F 18 injection, formerly MK-6240), as reported in the FDA approval notice from Lantheus investor releases. The product is a radioactive diagnostic injected before PET scanning, not a treatment, sponsored by Enigma Biomedical USA as a Lantheus/Cerveau Technologies product.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is this scan for?
- How does the scan work?
- How consistent are the results?
- What should patients know before scheduling?
Who is this scan for?
The scan is for adults with thinking or memory problems who are undergoing an Alzheimer's evaluation. It helps doctors detect neurofibrillary tangle pathology, one hallmark of Alzheimer's disease. Clinicians use the result with memory testing, medical history, brain exams, and other scans or lab tests.
In memory clinics, this combined workup helps characterize disease stage and guide trial or therapy selection. A doctor may consider it when the cause of impairment is uncertain. It is not a general brain-health screen or a standalone Alzheimer's test.
How does the scan work?
A small amount of F-18-labeled tracer is injected into a vein before PET imaging. The tracer sticks to tau tangles so the scanner can show their pattern. Readers then classify the scan as tau-positive or tau-negative.
The prescribed activity is about 185 MBq. Staff use standard radiation precautions plus hydration and frequent voiding after dosing. Patients can usually return to normal activity after the visit unless told otherwise.
How consistent are the results?
Approval rested on two studies in which five blinded readers classified 617 PET images, as described by the NeurologyLive approval summary from NeurologyLive. Readers showed strong agreement, which supports binary positive-or-negative use in clinics. Across readers, positive agreement was 68%-88% and negative agreement was 93%-99%, with Fleiss kappa about 0.86-0.92, according to the Pharmacy Times approval report from Pharmacy Times.
Negative scans were more consistent than positive scans. The studies met preset success criteria. Performance was mainly established by comparing amyloid-negative unimpaired people with amyloid-positive impaired people. That design means results apply less clearly to mixed or unclear cases.
What should patients know before scheduling?
Safety data in 1,734 subjects showed infrequent events, most often headache in 0.7% and nausea in 0.2%. Rare events included injection-site reactions, dizziness, and abdominal discomfort.
A negative scan does not rule out tau pathology. A positive scan alone does not confirm Alzheimer's disease. Safety and effectiveness are not established for non-Alzheimer tau diseases.
- Tell the clinic about smoking, medicines, and supplements, and avoid CYP1A2 inducers including smoking for 7 days before dosing
- Plan to drink water and urinate often after injection to clear tracer
- Pause breastfeeding for 4 hours after the dose
- Ask how this tau result will be combined with amyloid testing and clinical findings
You Might Also Like
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: A Source-Checked Briefing for Memory Clinic Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: A Source-Checked Briefing for Memory Clinic Patients
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: Benefits, Limits, and Evidence Gaps for Adult Children
